Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Sara Hijazo-Pechero und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) is a molecularly heterogeneous disease. In addition to genomic alterations, cancer transcriptional profiling can be helpful to tailor cancer treatment and to estimate each patient's outcome. Transcriptional activity levels of 50 molecular pathways were inferred in 4573 LUAD patients using Gene Set Variation Analysis (GSVA) method. Seven LUAD subtypes were defined and independently validated based on the combined behavior of the studied pathways: AD (adenocarcinoma subtype) 1–7. AD1, AD4, and AD5 subtypes were associated with better overall survival. AD1 and AD4 subtypes were enriched in epidermal growth factor receptor ( EGFR ) mutations, whereas AD2 and AD6 showed higher tumor protein p53 ( TP53 ) alteration frequencies. AD2 and AD6 subtypes correlated with higher genome instability, proliferation‐related pathway expression, and specific sensitivity to chemotherapy, based on data from LUAD cell lines. LUAD subtypes were able to predict immunotherapy response in addition to CD274 (PD‐L1) gene expression and tumor mutational burden (TMB). AD2 and AD4 subtypes were associated with potential resistance and response to immunotherapy, respectively. Thus, analysis of transcriptomic data could improve patient stratification beyond genomics and single biomarkers (i.e., PD‐L1 and TMB) and may lay the foundation for more personalized treatment avenues, especially in driver‐negative LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
- Preclinical and Experimental Research in Thoracic Tumors (PrETT), Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobrega…
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
- Neuro-Oncology Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
- Molecular Biology CORE, Center for Biomedical Diagnostics (CDB), Hospital Clínic de Barcelona, Spain.
ORCID-Profile: Ernest Nadal, Xavier Solé
Förderung
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- Ministerio de Ciencia, Innovación y Universidades
- European Regional Development Fund
Zitieren
APA
Hijazo-Pechero, S., Alay, A., Cordero, D., Marín, R., Vilariño, N., Palmero, R., Brenes, J., Montalban-Casafont, A., Nadal, E., & Solé, X. (2024). Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications. Molecular Oncology. https://doi.org/10.1002/1878-0261.13550
Vancouver
Hijazo-Pechero S, Alay A, Cordero D, Marín R, Vilariño N, Palmero R, et al. Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications. Molecular Oncology. 2024. doi:10.1002/1878-0261.13550
BibTeX
@article{HijazoPechero2024,
author = {Hijazo-Pechero, Sara and Alay, Ania and Cordero, David and Marín, Raúl and Vilariño, Noelia and Palmero, Ramón and Brenes, Jesús and Montalban-Casafont, Aina and Nadal, Ernest and Solé, Xavier},
title = {Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13550}
}
EUVIMED